To evaluate the potential use of a combination of antiresorption and bone formation-promoting agents as a treatment for postmenopausal osteoporosis, we examined the effects of combined and separate administration of estrogen ( 17,8-estradiol, 30 ;Lg/ kg per d, s.c.) and parathyroid hormone (rPTH 40 ;&g/ kg per d, s.c.) on the proximal tibia of ovariectomized (Ovx) rats. The treatments lasted for 4 wk and were initiated 1, 3, and 5 wk after surgery. Ovx resulted in rapid loss of cancellous bone volume (Cn-BV/TV) as well as trabecular connectivity, as determined by two dimensional strut analysis. When administered in a preventive mode, treatment beginning I wk postOvx, estrogen or PTH treatment alone preserved Cn-BV/TV and trabecular connectivity, and combined estrogen and PTH treatment caused a 40% increment in Cn-BV/TV while maintaining comparable trabecular connectivity with that seen in the Sham-operated animals. When administered in a curative mode to rats with established osteoporosis, treatments beginning 3 or 5 wk post-Ovx, estrogen or PTH treatment alone prevented further loss of connectivity and Cn-BV/TV, whereas the combined treatment resulted in as much as a 300% improvement in one of the parameters of trabecular connectivity, node to node strut length, and a 106% increase in Cn-BV/TV, with respect to the bone status at the initiation of treatment. The beneficial effects of this combined treatment derive from estrogen's ability to prevent accelerated bone resorption and, simultaneously, PTH's promotion of bone formation. These data demonstrate, in an animal model, that therapies can be devised to cure the skeletal defects associated with established osteoporosis. (J.
Introduction
Osteoporosis is a disease characterized by low bone mass, microarchitectural deterioration of bone tissue leading to enhanced bone fragility, and a consequent increase in fracture risk ( 1) . Two basic means of treatment have been proposed to combat bone loss in osteoporosis, namely, inhibition of bone resorption and promotion of bone formation. Estrogen (2), calcitonin (3) , and bisphosphonates (4) have been successful in preventing bone loss with small increments in bone mass but can not cure established osteoporosis as they do little to restore mass and trabecular connectivity. The ability to identify a regimen that can improve both bone mass and trabecular connectivity would be an important advance in treatment ofthe established disease. In humans, fluoride (5, 6) , anabolic steroids (7), and intermittent administration ofPTH (8-1 1 ) have been used with some success in improving cancellous bone mass. A therapeutic regimen using a combination of an antiresorptive agent, to prevent further bone loss, and an anabolic agent, to promote new bone formation, is a theoretically attractive approach for restoring bone mass. This treatment has not been rigorously tested in either humans or experimental animals.
Ovariectomy (Ovx)' induces osteoporosis in rats ( 12, 13) by increasing bone turnover ( 14, 15 ) and the rat has been successfully used as an animal model for postmenopausal osteoporosis (16, 17) . Estrogen prevents bone loss in this animal model by reducing bone turnover (18) (19) (20) (21) (22) while PTH, given intermittently, acts as an anabolic agent for bone formation (23) (24) (25) (26) (27) (28) (29) . In this study, we present data on changes in bone mass, as well as trabecular connectivity, as a result oftreatment ofOvx animals with estrogen and/or PTH. In addition, similar treatments were initiated at three different times after Ovx in order to ascertain the effects ofintervention in both preventive and curative modes. 1-5) (Table II) . The group treated with the combination of in the Ovx + V, weeks 5-9 rats. Combined PTH and estrogen PTH and estrogen, when administered in a curative mode from treatment resulted in improved cancellous bone volume when weeks 5 to 9 (Ovx + P + E, weeks 5-9), showed a 225% incompared with either PTH or estrogen treatment alone. Howcrease of cancellous bone volume when compared with the ever, the differences between Ovx + P + E and Ovx + P at untreated Ovx + V group killed on the same date (Ovx + V, weeks 3-7 and 5-9 were not statistically significant. Mean traweeks 5-9) (Table II) and a 106% increase when compared becular thickness was similar in Sham, Ovx + V, and Ovx + E with the untreated Ovx + V group killed at the time of the groups. All PTH treatments, whether Ovx + P or Ovx + P + E, initiation of treatment for this group (Ovx + V, weeks [1] [2] [3] [4] [5] increased the trabecular thickness by 25-40% (Table II) . The (Table II and Fig. 1 a) . Ovx + P + E through weeks 5-9 reaverage number of trabecular plates per square millimeter stored 84% of the cancellous bone volume relative to Sham, showed a time-dependent decrease in Ovx + V groups from 4.2 weeks 5-9, in contrast to a 74% loss ofcancellous bone volume before surgery to 2.0, 1.9, and 1.2 at 5, 7, and 9 wk after surgery, respectively. Each of the treatment groups showed significant preservation ofplate number (Table II) . For example, Ovx + P + E, weeks 5-9 showed a 166% increase when compared with Ovx + V, weeks 5-9 and a 60% increase when compared with the Ovx + V group killed at the time of the initiation of treatment for this treatment group (Ovx + V, weeks 1-5). Conversely, average plate separation increased rapidly with time in all Ovx + V from 189 ,um before surgery to 483, 519, and 1,343 Am at 5, 7, and 9 wk after surgery, respectively. Each treatment group displayed a lower degree ofplate separation than the Ovx + V groups; the combined treatment with PTH and estrogen group showed the lowest degree of separation at all time points (Table II) . Trabecular strut analysis. Three parameters which reflect trabecular connectivity, node to node strut length, node number, and node to terminus ratio, showed a significant decrease after ovariectomy (Table III) . In Ovx + V rats, only 11%, 4%, and 6% of node to node strut length were retained when compared to Sham at weeks 5, 7, and 9, respectively. PTH or estrogen alone helped to retain more node to node strut length (Ovx + P: 71%, 77%, and 23%; Ovx + E: 91%, 38%, and 10% at each of the time points, respectively). Rats treated with combined PTH and estrogen (Ovx + P + E, weeks 1-5), given in a preventive mode, retained 137% of their node to node strut length, a 1,100% improvement when compared with Ovx + V, weeks 1-5. When rats were treated with PTH and estrogen in a curative mode (Ovx + P + E, weeks 5-9), they retained 52% of their node to node strut length. This is an improvement of 700% when compared with Ovx + V killed after the same duration after Ovx (Ovx + V, weeks 5-9) and a 300% increase when compared with Ovx + V killed at the time ofinitiation oftreatment (Ovx + V, weeks 1-5) (Table III and Fig. b) . The other connectivity parameters, node number and ratio of node number to terminus number, showed a similar pattern (Table III 2482 Shen et al. and Fig. 1 c) . The parameter most reflecting loss of connectivand 82% higher than Sham at weeks 5, 7, and 9, respectively) ity, percentage terminus to terminus strut length to total strut and estrogen reversed this increase (-71%, -56%, and -71% of length, showed an increase of 81%, 123%, and 140% after ovarOvx + V at weeks 5, 7, and 9, respectively). PTH treatment iectomy when compared with the Sham groups at each time alone did not further elevate osteoclast surface in Ovx rats nor point, respectively (Table III and Fig. 1 d) . Each of the treatdid it override the suppressive effects ofestrogen (-64%, -72% ment groups displayed a greater degree of connectivity in traand -64% at weeks 5, 7, and 9, respectively) ( Table IV) . The becular structure. The combined PTH and estrogen treatment combined PTH and estrogen was similar to estrogen treatment was the most effective in improving connectivity.
Methods
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alone. Cellular activity parameters. Osteoclast surface, as a perThe bone formation rate was elevated after ovariectomy centage of bone surface, was elevated after Ovx (1 12%, 87%, (1 39%, 186%, and 324% at weeks 5, 7, and 9, respectively) when compared to Shams and severely inhibited by estrogen replacement when compared with Ovx + V (-72%, -55%, and -68% at weeks 5, 7, and 9, respectively) ( Table IV) . PTH increased the bone formation rate in Ovx animals, when give alone, by 40%, 65%, and 44% when compared with Ovx + V groups. Administration of PTH with estrogen dramatically increased bone formation rate by 382%, 242%, and 214% when compared with estrogen alone. The changes in bone formation rate were mainly affected by the changes in total labeled surface. There was an indication of a small increase in bone mineral apposition rate by PTH treatment but the trend was not consistent. There were no noticeable differences in the pattern ofchanges in bone formation rate or osteoclast surface whether the treatment was given in a preventive or curative mode. The cellular activity before and after treatments from 5 to 9 wk are shown in Fig. 1 , e andf. Bone mineral density. Bone mineral density measurements of the distal region of the femurs, enriched with cancellous bone, paralleled the cancellous bone volume results obtained from the proximal tibia (Table V and Fig. 1 g) . As expected, bone mineral density of the distal femurs in Ovx + V groups was 11-17% lower than respective Sham groups (Table V) . PTH treatment alone improved bone mineral density by 9%, 13%, and 15% when compared with respective Ovx + V groups at each of the three time points, respectively. The estrogen treatment alone prevented further bone loss and resulted in an increment of bone mineral density at the distal femur of 12%, 15%, and 16% when compared with respective Ovx + V groups. Bone mineral density ofthe distal femur in the Ovx + P + E group, treated in a preventive mode, from weeks 1 to 5 (Ovx + P + E, weeks 1-5), exhibited a 36% increase in bone mineral density when compared with the untreated group (Ovx + V, weeks 1-5). The Ovx + P + E groups treated in a curative mode, from weeks 5 to 9 (Ovx + P + E, weeks 5-9), showed a 32% increase of bone mineral density at the distal femur when compared with untreated Ovx + V groups sacrificed on the same date (Ovx + V, weeks 5-9) and a 29% increase when compared with untreated Ovx + V group sacrificed at the time of initiation of treatment for this group (Ovx + V, weeks 1-5) (Table V and Fig. 1 g) . Combined PTH and estrogen treatment resulted in a significantly improved bone mineral density of the distal femur when compared with either PTH or estrogen treatment alone (Table V) . The diaphyseal region of the femurs, enriched with cortical bone, showed little change in bone mineral density regardless of the time and type of treatment (Table V) .
Discussion
The importance of developing a therapeutic regimen that restores lost bone mass and trabecular structure in postmenopausal osteoporosis cannot be overly stressed. Whereas human studies to this end are tedious and time consuming, one can more rapidly and safely explore new therapeutic regimens by performing controlled animal studies. While there are some differences in the effects of estrogen deficiency on the skeleton of humans and rats, there are sufficient similarities between the responses of the two species to warrant use of this model to provide preliminary evaluation of a potential therapeutic approach ( 16, 17) . In this study, we have evaluated the effects of administering 1 7/3-estradiol, intermittent PTH, or a combination of both agents on bone mass and structure in ovariectomized rats. When PTH and estrogen were given in a preventive (from week 1) or curative (from week 3 or 5 post-Ovx) mode, both prevented estrogen deficiency-induced bone loss. The combination of PTH and estrogen treatment was superior to the use ofeither agent alone to increase mass and improve bone structure. The most dramatic impact of combined PTH and estrogen treatment was seen when they were given in a curative mode to rats with established osteoporosis. Our results demonstrate the possibility of a significant restoration of both cancellous bone volume and trabecular connectivity with combined use of PTH and estrogen. Blood and urine chemistry were found to be nondiscriminating, as is the case in human studies. Although the differences among groups did not reach statistical difference, the tubular reabsorption of phosphate, in general, is higher in Ovx rats and lower in estrogen-treated Ovx rats, a situation similar to that reported in humans (35) . The reason for the lack of phosphaturic effect of the PTH injection is probably due to the long interval between PTH administration and urine collection. Increased 1,25 (OH )2D levels after estrogen treatment in postmenopausal women has been proposed to be a possible mechanism of estrogen action in the prevention of bone loss (35, 36) . In ovariectomized rats, estrogen treatment resulted in either no change or inhibitory effects on the serum levels of 1,25(OH)2D while loss of bone mass was prevented (37) .
Thus, our results and others (37) indicate that, whereas the rat model mimics some of the sex steroid effects on bone, it is not ideal for studying the possible role of 1,25 (OH)2D in mediating the positive effects ofestrogen on the skeleton. As expected, PTH treatment alone increased 1,25 (OH)2D above that of Sham or Ovx + V groups. 1,25 (OH)2D levels were higher in the combined treatment groups than in the estrogen treatment groups, presumably the result of the administration of PTH. Increased levels of 1,25 (OH )2D have also been proposed to be related to the anabolic action of PTH (38) but a direct causeeffect relationship cannot be determined at this time. The pattern of osteocalcin expression appears to be related to the bone formation rate in our study. This is not surprising as it has been shown that the level of osteocalcin is positively correlated with the bone formation rate in humans (39, 40) . Increased osteocalcin has been linked to increased turnover in rats after Ovx as well (41, 42) . Whether the increased osteocalcin in PTHtreated groups is the result of increased 1,25 (OH)2D cannot be determined but 1,25(OH)2D has been shown to stimulate osteocalcin expression in vitro (43) .
Bone loss resulting from estrogen deficiency has been studied by bone mineral density and histomorphometric methods in rats and humans. We and others have previously shown by conventional methods of bone mass measurement, in humans and rats, that estrogen can prevent such bone loss. We have confirmed these observations by showing that estrogen can prevent further bone loss whether given early, in a preventive mode, or late, in a curative mode.
Whereas the total cancellous bone mass is important, the infrastructure of the cancellous bone lattice, or its degree of connectivity, may be equally or more important in determining its mechanical competence. Several techniques are now in use to analyze trabecular microarchitecture. Direct (44, 45) and indirect (32, 46) measurement of trabecular plate thickness, separation, and number have been used extensively. Less common methods to measure marrow and trabecular star volume (47) and trabecular bone pattern factors (48) are also available. Recently, a method for the analysis of two-dimensional trabecular structure was described by Garrahan et al. (33) , and adapted to a manual method in our laboratory (34) . Amongst the parameters measured, node number, node to node strut length, and node to terminus ratio are measures of connectivity of the trabecular plates while terminus to terminus strut length, as a percentage of total strut length, is an indicator of loss of connectivity (49) . We had demonstrated that ovariectomy (Ovx + V) reduces all indices ofconnectivity and increases the indices of disconnectivity and that estrogen replacement in these animals is capable of preventing the loss ofconnectivity. Based on the assumption that loss ofconnectivity precedes the loss of bone mass, such structural measurements would be a more sensitive indicator of bone destruction than bone mass measurements. This concept is supported by our findings that changes in connectivity parameters are more rapid and, thus, more severe than changes in bone mass parameters in Ovx animals.
Although the continuous elevation ofPTH has been considered catabolic in nature, the intermittent administration of PTH has been shown, by conventional bone mass measurements, to illicit an anabolic response in controlled rat (24, 26, 28, 29, 38, (50) (51) (52) and uncontrolled human (53) (54) (55) (56) and, thus, it is likely that the mechanical integrity of the new bone will be retained in rats treated with PTH plus estrogen. The improvement in cancellous bone volume is corroborated by an improvement of the bone mineral density in the cancellous bone-enriched distal region, but not the cortical-bone enriched diaphyseal region, of the femurs. Although our results were derived from long bones, there have been reports of comparable observations in cancellous bone of the axial skeleton, such as the vertebra, both in estrogen-or PTH-treated animals (51, 56, 57) . Therefore, it is likely that our findings may be valid for other trabecular sites as well, although this awaits confirmation.
One concern regarding the use of PTH as an anabolic agent for cancellous bone is that the increase in cancellous bone volume could be achieved at the expense of cortical bone, as suggested in a previous human study (10 Thus, in ensuing studies, 1 ,25-(OH )2D was given together with PTH to prevent the possible loss ofcortical bone. As an alternative to the above approach, we decided to combine an antiresorber, estrogen, with PTH in order to protect against cortical bone loss. This takes advantage of the idea that estrogen has been shown to be very effective in preventing cortical bone loss (2) and also increases l,25-(OH)2-D levels in humans (35) . In short-term rat studies by Gunness-Hey and Hock (24) , PTH has been shown to increase cancellous bone without reducing cortical bone. We have confirmed their findings in this study. The rat model may differ from humans because of the high calcium content in the diet, an exuberant 1,25-(OH)2D response to PTH and the better efficiency of intestinal calcium absorption due to the relatively young age of the animals. A similar study with aged animals, given a moderate calcium diet, may be more appropriate in deciphering the role of 1,25-(OH)2D and/or estrogen in preventing cortical bone loss.
Although our findings are exciting, these experiments only address some of the important issues and many questions remain to be answered. For example, what are the prolonged effects of such combined treatment, does bone restored by combined treatment remain structurally intact after the treatment is terminated, or will continued estrogen supplementation alone will be sufficient to maintain the restored bone? Nevertheless, our results strongly support the possibility of restoring bone health in established postmenopausal osteoporotic subjects with a combined PTH and estrogen treatment. A controlled clinical trial using the combination of estrogen and PTH is clearly well warranted.
